ClinicalTrials.gg
Status unknownNCT05790096Updated Mar 29, 2023

Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy

A Phase 3 interventional study of Granulokine and Filgrastine in Breast Cancer, sponsored by Blau Farmaceutica S.A.. Status unknown. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by Blau Farmaceutica S.A. · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

Randomized Study of the Clinical Efficacy and Safety of Filgrastine® in Patients with Breast Cancer Treated with Myelotoxic Chemotherapy.

Primary Objective: to evaluate the activity and safety of Filgrastine® in Brazilian patients undergoing adjuvant treatment for breast cancer, with the frequency of grade 4 neutropenia in the first cycle of chemotherapy as the primary endpoint.

Secondary Objectives:

  • Frequency of febrile neutropenia during treatment;
  • Frequency of neutropenia of any degree in the first cycle;
  • Frequency of hospitalization during treatment;
  • Duration of grade 4 neutropenia in the first treatment cycle;
  • Toxicity during treatment;
  • Immunogenicity throughout treatment.

All endpoints will be descriptively analyzed in both groups of patients.

Study design Randomized (2:1), open-label, multicenter study.

Chemotherapy will be given on the first day of each cycle of treatment, for a maximum of four to eight cycles, depending on the regimen, patients whose chemotherapy treatment is prolonged beyond this period being withdrawn from the study.

Patients will be evaluated through laboratory tests, including complete blood count, biochemistry and anti-filgrastim antibodies.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 60 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Blau Farmaceutica S.A. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of the Free and Form by written;
  • Female sex;
  • Age between 18 and 75 years old;
  • Diagnosis of breast cancer confirmed by cytology or histopathology;
  • Disease in stages II or III, according to the classification tumor-node- (TNM);
  • Indication of chemotherapy with full dose of one of the regimens eligible;
  • Performance status of 0 or 1;
  • Appropriate body functions ( [CAN] ≥1,500/mm³; count ≥150,000/mm³; serum creatinine ≤1.2 mg/dL; and transaminases ≤1.5 times the ).

Exclusion criteria

Exclusion Criteria:

  • Previous use of chemotherapy;
  • Previous use of filgrastim;
  • Prediction of prophylactic or therapeutic use of antibiotics, antifungals or antivirals in the first cycle of chemotherapy;
  • Previous radiotherapy involving the pelvis or radiotherapy from any site within the last 6 weeks prior to randomization;
  • History of bone marrow transplantation (as a recipient);
  • Presence of other neoplasms;
  • Presence of severe co-morbidities;
  • Recent (\<6 months) or planned participation in other studies clinical trials involving drugs of any nature or in studies of any form of intervention;
  • Known intolerance or allergy to any of the components the filgrastim formulations evaluated in the study;
  • Pregnancy or lactation (patients of must have a negative serological pregnancy test dated within 7 days prior to randomization).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Reference Drug - Granulokine®

    Reference Drug - Granulokine® is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim. Granulokine® will be administered at a daily dose of 5 μg/kg of body weight, exclusively subcutaneously, according to randomization.

    Biological: Granulokine

  • Experimental
    Test Drug - Filgrastine®

    Test Drug - Filgrastine® is presented in boxes containing vials containing 1 mL of solution for injection and 300 µg of filgrastim. Filgrastine® will be administered at a daily dose of 5 μg/kg of body weight, exclusively subcutaneously, according to randomization.

    Biological: Filgrastine

Interventions

  • BiologicalGranulokine

    Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.

  • BiologicalFilgrastine

    Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.

06

What researchers measure

Primary outcomes

  1. frequency of grade 4 neutropenia in the first cycle of chemotherapy in the group of patients treated with Filgrastine®

    Time frame: 1 month

Secondary outcomes

  1. Frequency of febrile neutropenia during treatment;

    Time frame: maximum 5 months

  2. Frequency of neutropenia of any degree in the first cycle;

    Time frame: 1 month

  3. Frequency of hospitalization during treatment;

    Time frame: maximum 5 months

  4. Duration of grade 4 neutropenia in the first treatment cycle

    Time frame: 1 month

  5. Adverse event monitoring

    Any adverse event that occurs from Treatment Visit 1 (first day of medication) onwards will be followed through to the Final Visit or until your resolution of the event, whichever is later

    Time frame: maximum 5 months

  6. assessment of Immunogenicity throughout treatment by antigenic radiometric tests or ELISA

    The immunogenicity of filgrastim will be evaluated by antigenic radiometric tests or ELISA (enzyme-linked immunosorbant assay) to detect the formation of anti-G-CSF antibodies. All information will be recorded in the clinical form of the study.

    Time frame: maximum 5 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2023; primary completion for Jun 2024, 13 months later.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 13 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2023
First posted
Mar 29, 2023
StartEst.
May 2023
Primary completionEst.
Jun 2024
CompletionEst.
Dec 2024
Last update
Mar 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05790096
Lead sponsor
Blau Farmaceutica S.A.
Responsible party
Sponsor
First posted
Mar 29, 2023
Start date
May 2023 (estimated)
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 29, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion